6 results
Primary objective: to investigate the safety of RFA in non-metastasized, irresectable locally advanced pancreatic cancer.Secondary objectives: to determine VAS pain score, length of hospital stay, survival, progression free survival and CA19-9…
The predictive value of the microbiome (throat swabs and stool samples) to identify patients who will relapse during durvalumab treatment after CRT (False negative Rate) at 6 months. Exploratory endpoints include the effects of antibiotic therapy…
The objective of this study is to evaluate the effects of sotatercept treatment (plus maximum tolerated background PAH therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung…
This study will assess the safety and tolerability of sotatercept in pediatric participants with PAH WHO Group 1 who receive PAH background therapy. In the absence of treatment, the majority of patients succumb to heart failure within a few years of…
Primary:The primary objective of this open-label, LTFU study is to evaluate the long-term safety and tolerability of sotatercept when added to background PAH therapy in adult participants with PAH.Secondary:The secondary objective is to follow…
The aim of the PELICAN trial is to investigate the survival benefit of RFA followed by chemotherapy as compared to standard palliative chemotherapy alone in patients with LAPC.